Hackney J F, Schwartz D A
Department of Pharmacology and Therapeutics, University of South Florida College of Medicine, Tampa 33612.
J Steroid Biochem. 1988 Jan;29(1):15-9. doi: 10.1016/0022-4731(88)90370-6.
The antifungal drug, ketoconazole, was reported to antagonize the induction of the enzyme tyrosine aminotransferase (TAT) by glucocorticoids in hepatoma tissue culture (HTC) cells, and to compete with glucocorticoids for binding to the glucocorticoid receptor. Since glucocorticoids inhibit the growth of the human leukemia cell line CEM-C7, ketoconazole might be expected to reverse this inhibition. Unexpectedly, ketoconazole inhibited CEM-C7 cell growth without utilizing glucocorticoid receptors. This was confirmed by ketoconazole inhibition of the growth of a receptor-less subline of CEM-C7 cells which are insensitive to glucocorticoids. Ketoconazole competed with triamcinolone acetonide (TA) for binding to the glucocorticoid receptor in cell-free supernatant prepared from CEM-C7 cells, but this was greatly reduced if ketoconazole and TA were incubated with intact cells prior to preparation of the cell-free supernatant. Ketoconazole inhibited induction by TA of the enzyme glutamine synthetase only at concentrations of 45-90 microM. We conclude that ketoconazole antagonism of glucocorticoid activity in CEM-C7 cells is probably not of pharmacologic significance due to the large concentrations required, and its reduced interaction with receptors in intact cells. The growth inhibitory activity of ketoconazole may be of interest in cancer chemotherapy.
据报道,抗真菌药物酮康唑可在肝癌组织培养(HTC)细胞中拮抗糖皮质激素对酪氨酸转氨酶(TAT)的诱导作用,并与糖皮质激素竞争结合糖皮质激素受体。由于糖皮质激素可抑制人白血病细胞系CEM-C7的生长,因此预计酮康唑可能会逆转这种抑制作用。出乎意料的是,酮康唑在不利用糖皮质激素受体的情况下抑制了CEM-C7细胞的生长。这一点通过酮康唑对CEM-C7细胞中对糖皮质激素不敏感的无受体亚系细胞生长的抑制作用得到了证实。酮康唑在从CEM-C7细胞制备的无细胞上清液中与曲安奈德(TA)竞争结合糖皮质激素受体,但如果在制备无细胞上清液之前将酮康唑和TA与完整细胞一起孵育,这种竞争作用会大大降低。酮康唑仅在45-90微摩尔浓度时抑制TA对谷氨酰胺合成酶的诱导作用。我们得出结论,由于所需浓度较高且其与完整细胞中受体的相互作用减弱,酮康唑在CEM-C7细胞中对糖皮质激素活性的拮抗作用可能没有药理学意义。酮康唑的生长抑制活性在癌症化疗中可能会受到关注。